Q1 Earnings Estimate for DAWN Issued By HC Wainwright

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a research report issued on Thursday, October 31st. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.20) EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the prior year, the firm earned ($0.54) earnings per share.

Several other research analysts have also commented on the company. Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. JPMorgan Chase & Co. reduced their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $14.81 on Monday. The firm’s 50 day moving average price is $14.20 and its 200 day moving average price is $14.38. Day One Biopharmaceuticals has a 1 year low of $10.90 and a 1 year high of $18.07. The firm has a market cap of $1.49 billion, a P/E ratio of -14.38 and a beta of -1.51.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the business. TimesSquare Capital Management LLC grew its position in Day One Biopharmaceuticals by 8.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock worth $25,460,000 after acquiring an additional 139,160 shares during the last quarter. SteelPeak Wealth LLC boosted its stake in Day One Biopharmaceuticals by 9.8% in the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after acquiring an additional 1,550 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 87.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,203 shares of the company’s stock worth $267,000 after acquiring an additional 8,935 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at about $2,566,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Insider Activity at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Charles N. York II sold 2,633 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the completion of the transaction, the chief financial officer now directly owns 232,485 shares in the company, valued at $3,254,790. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the sale, the insider now directly owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,248 shares of company stock valued at $697,082. Insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.